Navigation Links
Cantel Medical's Mar Cor Purification Subsidiary Acquires Hemodialysis Water Business from Siemens' Water Technologies Business Unit
Date:3/25/2013

idiary of Cantel Medical Corp., Mar Cor Purification is dedicated to providing innovative solutions through filtration, water purification, and disinfection technologies to the medical, life science and industrial marketplaces. Mar Cor Purification has service offices in 22 cities in the U.S. and Canada, with 7 resin regeneration plants strategically located in Atlanta, Boston, Chicago, Philadelphia, San Antonio, Montreal and Toronto. For more information please visit http://www.mcpur.com.       

About Cantel Medical Corp.

Cantel Medical Corp. (NYSE: CMN) is a leading provider of infection prevention and control products in the healthcare market. Our products include water purification equipment, sterilants, disinfectants and cleaners, specialized medical device reprocessing systems for endoscopy and renal dialysis, disposable infection control products primarily for dental and GI endoscopy markets, dialysate concentrates and other dialysis supplies, hollow fiber membrane filtration and separation products for medical and non-medical applications, and specialty packaging for infectious and biological specimens. We also provide technical maintenance for our products and offer compliance training services for the transport of infectious and biological specimens. 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel's filings and reports with the Securities and Exchange Commission. Such forward
'/>"/>

SOURCE Cantel Medical Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cantel Medical Reports EPS of $0.38 vs. $0.27 on 9% Sales Increase for Second Quarter Ended January 31, 2013
2. Cantel Medical Reports EPS of $0.35 vs. $0.23 for First Quarter Ended October 31, 2012
3. Cantel Medical Appoints Jorgen B. Hansen As Executive Vice President And Chief Operating Officer
4. Cantel Medical Corp. To Present At The CL King 10th Annual Best Ideas Conference
5. Cantel Medical Board Of Directors Authorizes Regular Semiannual Dividend
6. IQAirs New Edition Redefines High-Performance Air Purification
7. Takeda Launches New Subsidiary in Ecuador
8. Generex Touts Pipeline Potential of Antigen Express Subsidiary
9. Novation Holdings Announces Sale of Subsidiary
10. Golden Meditech Holdings Limited Announces Updates on Medical Devices Subsidiary Latest Development
11. China Biologics Guizhou Taibang Subsidiary Donates Lifesaving Plasma Products for the Injured in the Yunnan Earthquake
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... of, collaboration with investigators worldwide to develop new treatments for ... diverse forms of cancer ... on relapse rate of patients with early-stage breast cancer, - Four oral ... results of RECORD-1 study in renal cell ...
... Mich. and TOULOUSE, France, May 15 ... company,developing HDL-related compounds for the treatment of ... has completed a Phase I,clinical trial for ... candidates.,CER-002 is a peroxisome proliferator-activated receptor (PPAR),delta-specific ...
Cached Medicine Technology:Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease 2
(Date:4/24/2014)... Ever since it was first identified more than ... to play an integral role in preventing the onset ... either lost or mutated, malignant cells can grow unchecked ... by investigators at Beth Israel Deaconess Medical Center (BIDMC) ... effects and how its loss or alteration can set ...
(Date:4/24/2014)... TORONTO Baker,s yeast is giving scientists a better ... of hospitalization and illness world-wide. , When two ... one can suppress or enhance the effectiveness of the ... of another. These types of interactions are a major ... severe practical limits on the practical scope of drug ...
(Date:4/24/2014)... stressful outcomes for parents who have a child born ... a recent study led by a researcher at the ... and life-changing and stress levels high, the vast majority ... positive outcomes as well, a phenomenon known as posttraumatic ... of the American Journal of Orthopsychiatry . , ...
(Date:4/24/2014)... 24, 2014 ,Take me out to the ballgame, ... kale chips. The more likely culprits include French fries, ... Unfortunately for children who play youth baseball, eating unhealthy ... weight problems, according to researchers at Wake Forest Baptist ... edition of Childhood Obesity , found that high-calorie ...
(Date:4/24/2014)... the Center for BrainHealth will bring together national ... brain-related challenges at its inaugural Brain Health Summit, ... Featured speakers will include Dr. Sandra Bond Chapman, ... BrainHealth, U.S. Senator Chuck Grassley (R-IA), U.S. Representative ... Secretary for Policy and Early Learning, U.S. Department ...
Breaking Medicine News(10 mins):Health News:Surprising new insights into the PTEN tumor suppressor gene 2Health News:Surprising new insights into the PTEN tumor suppressor gene 3Health News:Large-scale identification and analysis of suppressive drug interactions 2Health News:Parents of severely ill children see benefits as caregivers, says study 2Health News:Take the bat, leave the candy 2Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2
... The discovery 15 years ago that the genes BRCA1 ... cancer was a breakthrough for cancer prediction and therapy, ... Prof. Alfons Meindl (Klinikum rechts der Isar of the ... Germany, the U.K., and the U.S., can identify another ...
... likely to be screened, study finds , WEDNESDAY, April 21 ... are being screened for skin cancer, a particular problem among ... common cancer screenings, a new study has found. , Researchers ... and older, who took part in the 2005 National Health ...
... ... , ... (Vocus) April 21, 2010 -- SafeShot Technologies, LLC , a leader in safety ... Emeritus Professor of Surgery at Keck School of Medicine, University of Southern California. Dr. ...
... Washington, DC -- For women with hormone receptor-positive breast ... daily dose of an anti-hormone drug will block the ... breast cancer at bay. The treatments work like ... resistant to therapy. With no other treatment options, ...
... clinical trials have shown that non-steroidal anti-inflammatory drugs ... colon cancer and precancerous polyps in humans. Now, ... that an investigational form of naproxen, called nitric ... earliest molecular changes that lead to colorectal cancer ...
... taken a major step forward in the understanding of ovarian ... Researchers have found that patients with hereditary ovarian cancer ... more likely to experience secondary tumours in their liver and ... is better than other patients. In non-hereditary cancer, ovarian ...
Cached Medicine News:Health News:Researchers identify a new breast and ovarian cancer susceptibility gene 2Health News:Few Over 50 Get Skin Cancer Screenings 2Health News:SafeShot Technologies Names Dr. Robert W. Beart as New Chief Executive Officer 2Health News:SafeShot Technologies Names Dr. Robert W. Beart as New Chief Executive Officer 3Health News:1 big problem with many possible solutions 2Health News:1 big problem with many possible solutions 3Health News:1 big problem with many possible solutions 4Health News:1 big problem with many possible solutions 5Health News:1 big problem with many possible solutions 6Health News:1 big problem with many possible solutions 7Health News:Researchers show that nitric oxide-donating naproxen can boost colorectal cancer prevention 2Health News:Ovarian cancer study offers vital clues for new therapies 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: